Price
$3.82
Increased by +2.69%
Dollar Volume
48.38 K
ADR%
4.23
Earnings Report Date (estimate)
Mar 27, 23 (-0.93)
Market Cap.
18.55 M
Shares Float
4.84 M
Shares Outstanding
4.86 M
Beta
1.66
Price / Earnings
-48.35
BPR
14.88
20D Range
3.37 3.94
50D Range
2.89 4.00
200D Range
2.89 8.75
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 3, 22 -0.70
Decreased by -40.00%
-0.68
Decreased by -2.94%
Aug 3, 22 -0.87
Decreased by -74.00%
-0.68
Decreased by -27.94%
May 11, 22 -0.50
Decreased by -100.00%
-0.50
May 9, 22 -0.50
Increased by 0.00%
-0.50
Mar 29, 22 -0.50
Decreased by -300.00%
-0.50
Mar 27, 22 -0.50
Increased by +93.33%
-0.50
Nov 4, 21 -0.25
Increased by +96.77%
-0.50
Increased by +50.00%
Nov 7, 19 -0.50
Increased by +86.67%
-4.25
Increased by +88.24%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 1.86 M
Increased by +210.52%
-3.42 M
Decreased by -67.73%
Decreased by -183.87%
Increased by +45.98%
Mar 31, 22 1.52 M
Increased by +158.87%
-2.64 M
Decreased by -82.70%
Decreased by -174.03%
Increased by +29.43%
Dec 31, 21 3.47 M
Increased by +46.79%
-3.19 M
Decreased by -143.02%
Decreased by -91.74%
Decreased by -65.56%
Sep 30, 21 602.00 K
Increased by +370.31%
-1.70 M
Decreased by -49.47%
Decreased by -282.06%
Increased by +68.22%
Jun 30, 21 599.00 K
Increased by +780.88%
-2.04 M
Increased by +40.90%
Decreased by -340.40%
Increased by +93.29%
Mar 31, 21 586.00 K
Decreased by -46.24%
-1.45 M
Decreased by -285.49%
Decreased by -246.59%
Decreased by -445.03%
Dec 31, 20 2.37 M
Increased by +13.04 K%
-1.31 M
Decreased by -30.32%
Decreased by -55.41%
Increased by +99.01%
Sep 30, 20 128.00 K
Decreased by -54.77%
-1.14 M
Decreased by -243.20%
Decreased by -887.50%
Decreased by -658.80%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and to develop human 3D intestinal tissue models to study infection biology; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd., Novo Nordisk Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.